Ligand Pharmaceuticals LGND
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
About
Ligand Pharmaceuticals (LGND) Business Model and Operations Summary
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.
Key Insights
Ligand Pharmaceuticals (LGND) Core Market Data and Business Metrics
Market Cap
$1.89 BillionTotal Outstanding Shares
19.26 Million SharesTotal Employees
68Dividend
No dividendIPO Date
February 2, 1995SIC Description
Pharmaceutical PreparationsPrimary Exchange
NASDAQHeadquarters
3911 Sorrento Valley Blvd, San Diego, CA, 92121
Historical Stock Splits
If you bought 6 shares of LGND before November 19, 2010, you'd have 1 share today.
| Execution Date | Split Amount |
|---|---|
| November 19, 2010 | 1-for-6 (Reverse Split) |
Short Interest
Short Interest
This information is bi-monthly aggregated short interest data reported to the Financial Industry Regulatory Authority (FINRA) by broker-dealers.
Short Interest: The total number of shares that have been sold short but have not yet been covered or closed out.
Bi-Weekly Change (%): The percentage change in short interest from the previous bi-weekly period.
Settlement Date: The date on which the short interest data is considered settled, typically based on exchange reporting schedules.
Days to Cover: The estimated number of days it would take to cover all short positions based on average trading volume.
Track Short Interest Levels to Gauge Bearish Market Sentiment and Short Squeeze Potential
| Short Interest | Bi-Weekly Change (%) | Settlement Date | Days to Cover |
|---|---|---|---|
| 955,114 Shares | +22.44% | 3/14/2025 | 7.09 |
| 780,075 Shares | -7.68% | 2/28/2025 | 6.17 |
| 844,954 Shares | -11.20% | 2/14/2025 | 12.49 |
| 951,520 Shares | +4.40% | 1/31/2025 | 11.85 |
| 911,388 Shares | +1.25% | 1/15/2025 | 9.41 |
| 900,125 Shares | +10.74% | 12/31/2024 | 5.93 |
Cash Flow Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Financing Activities, Continuing | $97.14 Million |
| Net Cash Flow From Operating Activities | $97.05 Million |
| Exchange Gains/Losses | $-1.17 Million |
| Net Cash Flow From Operating Activities, Continuing | $97.05 Million |
| Net Cash Flow, Continuing | $50.52 Million |
| Net Cash Flow From Financing Activities | $97.14 Million |
Income Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Diluted Average Shares | $18.29 Million |
| Research and Development | $21.43 Million |
| Income Tax Expense/Benefit, Deferred | $-15.80 Million |
| Income/Loss From Equity Method Investments | $-12.82 Million |
| Revenues | $167.13 Million |
| Benefits Costs and Expenses | $164.62 Million |
Comprehensive Income
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
| Comprehensive Income/Loss Attributable To Parent | $-9.16 Million |
| Comprehensive Income/Loss | $-9.16 Million |
| Other Comprehensive Income/Loss | $-9.16 Million |
Balance Sheet
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Liabilities And Equity | $941.77 Million |
| Other Current Assets | $315.51 Million |
| Accounts Payable | $5.23 Million |
| Equity Attributable To Noncontrolling Interest | $0 |
| Other Non-current Assets | $328.43 Million |
| Noncurrent Liabilities | $74.22 Million |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||